Psychotherapy With Persons With Parkinson’s Disease

Elizabeth Bates Freed

Citation

Bates Freed, E. (2019). Psychotherapy with persons with Parkinson’s disease. Journal of Health Service Psychology, 45, 91–95.

Abstract

Parkinson’s disease is most recognized by its motor symptoms, but it also triggers a vast array of neuropsychological symptoms that can be targets for nonpharmacological, as well as pharmacological, therapeutic interventions. Individuals with Parkinson’s disease will generally struggle with anxiety, depression, and cognitive difficulties as well as issues of preservation of core identity, purpose, and meaning as the disease progresses. These are all reasonable targets to address in psychotherapy.

Registrants can read the full article on CE.NationalRegister.org

References

Aarsland, D. , Ballard, C. , Larsen, J. P. and McKeith, I. (2001), A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson’s disease with and without dementia. Int. J. Geriat. Psychiatry, 16: 528-536. doi:10.1002/gps.389

Ascherio, A. and Schwarzschild, M.A. (2016). The epidemiology of Parkinson’s Disease: Risk factors and prevention. Lancet Neurology 15:1257-72.

Bellou, V., Belbasis, L., Tzoulaki, I., Evangelou, E., Ioannidis, J. P. A. (2016). Environmental risk factors and Parkinson’s disease: An umbrella review of meta-analyses. Parkinsonism and Related Disorders 23: 1-9.

Fenelon, G., & Alves, G. (2010). Epidemiology of psychosis in Parkinson’s disease. Journal of the Neurological Sciences, 289 (1-2), 12-17. doi:10.1016/J.JNS.2009.08.014

Gomperts, S. N. (2016). Lewy Body Dementias: Dementia with Lewy Bodies and Parkinson Disease Dementia. Continuum 22(2 Dementia): 435-463.

Hirsch, L., Jette,N., Frolkis, A., Steeves, T., & Pringsheim, T. (2016). The incidence of PD: A systematic review and meta-analysis. Neuroepidemiology 46(4):292-300. doi: 10.1159/000445751. Epub 2016 Apr 23.

Kampling, H., Brendel, L. K., Mittag, O. (2019). (Neuro)Psychological interventions for non-motor symptoms of patients with Parkinson’s diseae: A systematic umbrella review. Neuropsychology Review 29:166-180.

Marras, C., Beck, J. C., Bower, J. H., Roberts, E., Ritz, B., Ross, G. W., … Parkinson’s Foundation P4 Group (2018). Prevalence of PD across North America. NPJ PD, 4, 21. doi:10.1038/s41531-018-0058-0

Menza, M., Dobkin, R. D., Marin, H., & Bienfait, K. (2010). Sleep disturbances in PD. Movement Disorders : Official Journal of the Movement Disorder Society, 25 Suppl 1(Suppl 1), S117–S122. doi:10.1002/mds.22788

Nagy, A. and Schrag, A. (2019). Neuropsychiatric aspects of PD. Journal of Neural Transmission 126: 889-896.

Pedersen, K. F., Alves, G., Aarsland, D., & Larsen, J. P. (2009). Occurrence and risk factors for apathy in Parkinson disease: A 4-year prospective longitudinal study. Journal of Neurology, Neurosurgery & Psychiatry, 80(11), 1279–1282. https://doi-org.antioch.idm.oclc.org/10.1136/jnnp.2008.170043

Perestelo-Perez, L., Rivero-Santana, A., Perez-Ramos, J., Serrano-Perez, P., Panetta, J., and Hilarion, P. (2014). Deep brain stimulation in Parkinson’s disease: meta-analysis of randomized controlled trials. J. Neurology 261:2051-2060.

Pigott, K., Rick, J., Zie, S., et al. (2015). Longitudinal study of normal cognition in PD: Preliminary analysis from the French COPARK cohort. Eur. J. Neurol. 19:28-37.

Reich, S. G., and Savitt, J. M. (2019). Parkinson’s Disease. Med. Clin. N. Am. 103:337-350).

Ruiz, R. M., Evans, A.H., Velakoulis, D., and Looi, J.C.L., 2016. Neuropsychiatric manifestations of PD. Australasian Psychiatry 24(6): 529-533.

Seppi, K., Chaudhuri, K.R., Coelho, M., Fox, S.J., Katzenschlanger, R., et al., (2019). Update on treatments for nonmotor symptoms of PD, Movement Disorders 54(2): 180-196.

Sveinbjornsdottir, S., 2016. The clinical symptoms of PD. 139(Suppl 1): 318-324.